Few & Far Between: How Biotech Gets Built

Episode 74: Jason Tardio, President and COO, Immunic Therapeutics

Today on the Biorasi Few & Far Between Podcast: Host Melissa Alesse welcomes Jason Tardio, President and COO of Immunic Therapeutics, to the podcast to explore the biote

Episode 73: Isaac Stoner, CEO, MindImmune Therapeutics, Inc.

Today on the Biorasi Few & Far Between podcast: Host Melissa Alesse welcomes Isaac Stoner, CEO of MindImmune Therapeutics, back to the podcast for a conversation on the

Episode 72: Joel White, Owner, Marketcap Consulting

Today on the Biorasi Few & Far Between podcast: What's trending in the CRO market? Find out as host Melissa Alesse welcomes Joel White, owner of Marketcap Consulting and

Episode 71: Chris O'Brien, Former ⁨Biorasi⁩ CEO and Current CEO of ⁨Rancho Biosciences

Today on the Biorasi Few & Far Between podcast: Join new host Melissa Alesse and former host Chris O'Brien - CEO at Rancho BioSciences and Biorasi Board member - as the

Episode 69: Zak Kohane, Chair of the Department of Biomedical Informatics at Harvard Medical School

Today on the Biorasi podcast, we look back on three years of AI innovation in healthcare and clinical trials - breaking new boundaries and a creating a new reality across

Video Episode 68: Sinan Gölhan, CEO at GelTech Labs

How do today’s CEOs and founders find the balance between planning and entrepreneurship? Check out the latest episode of the Biorasi Few & Far Between podcast - How Biot

Video Episode 67: Aoife Brennan, President and CEO of Climb Bio

Let's kick off 2026 with the first Biorasi podcast episode of the year! How do you get "Biotech Vision" to see the complete picture of your place in the industry? Find

Episode 66: Mark Abelson, Founder of Ora Clinical

Are clinical trial protocols a true art form? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Mark Ableson, founder

Video Episode 65 - Amit Etkin, Founder and CEO of Alto Neuroscience

With biotech, is it the destination, the journey, or both? Find out in a new episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes guest Amit Etk

Video Episode 64 - Professor Justin Stebbing

Will GLP-1's one day replace our morning coffee? Find out in a special video episode of the Few & Far Between podcast! Host Chris O'Brien welcomes friend of the show, P

Video Episode 63 - Bruce Leuchter, MD, President and CEO of Neurvati Neurosciences

What if the future of biotech is actually late-stage execution? Welcome to our first video episode of the Biorasi Few & Far Between podcast with your host, Chris O’Brien

Episode 62: Ken Suzuki, Chief Marketing Officer at Nautilus Biotechnology

When is the right time for a biotech to bring in a Chief Marketing Officer/CMO? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Bri

Episode 61: Woody Bryan, President and CEO of Revolo Biotherapeutics

Why is a feather-light touch important in fighting infections? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Woody

Episode 60: Part Two: Yochi Slonim, Co-Founder and CEO at Anima Biotech

Can AI see and talk to human cells? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-Founder and CEO at

Episode 59, Part One: Yochi Slonim, Co-Founder and CEO at Anima Biotech

What do software bugs and human cells have in common? Find out in today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien welcomes Yochi Slonim, Co-

Episode 58: Jerry McLaughlin, CEO and Board Member at Life Biosciences

How does a biopharma background prepare you for the biotech playground? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welco

Episode 57: Jim Brown, DVM, President and CEO of DURECT Corporation

Is the epigenome the "software" of the cell nucleus? Find out in our latest episode of the Biorasi Few & Far Between podcast! Host Chris O'Brien welcomes Jim Brown, Pres

Episode 56, Part Two: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

How do experienced troubleshooters solve a difficult problem? By asking the right questions first! Welcome back to part two of our conversation with Michael Tolentino, M

Episode 55: Julio G. Martinez-Clark, CEO and Co-Founder at bioaccess®

How much do you know about clinical trials in Latin America? Take a deep dive with us as we explore the benefits and risks of running studies in this region. In our late

Episode 54, Part One: Michael Tolentino, MD, Co-Founder and Head Scientific Consultant, Aviceda Therapeutics

The challenge? Decoding the human immune system. Get ready to meet the top challenger on today's episode of the Biorasi Few & Far Between podcast. Host Chris O'Brien wel